ANA-associated arthritis: clinical and biomarker characterization of a population for basket trials
Authors' conclusion
We defined ANA-associated arthritis, a more clinically and immunologically homogeneous population than existing RMD populations for trials, and a more prevalent population for therapies in the clinic.
Study context
- Population
- Patients with ANA-associated RMDs (SLE, pSS, scleroderma, inflammatory myositis, MCTD and UCTD)
- Participants
- 294 patients
- Exposure
- High musculoskeletal (MSK) disease activity cluster vs low MSK disease activity cluster
- High MSK disease activityn = 89
- Low MSK disease activityn = 124reference
- Outcome
- Prevalence of MSK inflammation (ANA-associated arthritis)
Methodological detailsmultidisease, Gaussian mixture modelling reclustering
- Multidisease
- Gaussian mixture modelling reclustering
Main finding
As reported in the abstract
Prevalence of inflammatory MSK symptoms (ANA-associated arthritis) across ANA-associated RMDs
Inflammatory MSK symptoms prevalent across ANA-associated RMDs
213 of 294
Observational data: associations, not effects.
Further findings
Variables across diagnoses in ANA-associated arthritis
- Most variables did not differ between diagnoses; EQ5D-5L index and mobility domains lower in MCTD/pSS
- both P < 0.05
- Therapy use differed significantly; biologic use greatest in SLE
- P < 0.05
- FM and OA prevalence similar across diagnoses
High vs low MSK disease activity cluster features
- High cluster: significantly higher prednisolone usage, physician global assessment (PGA), Sm/RNP/SmRNP/chromatin positivity, Tetherin mean fluorescence intensity (MFI) and IFN Score-A activity
- High cluster: numerically lower FM and OA prevalence
Original publication
ANA-associated arthritis: clinical and biomarker characterization of a population for basket trials. Rheumatology (Oxford). Published 1 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →